Principal Pharmacist at Guy's and St Thomas' NHS Foundation Trust
Chronic obstructive pulmonary disease: clinical phenotypes and implications for managementSubscription
Phenotyping patients with chronic obsructive pulmonary disease allows their separation into distinct categories that differentiate their prognosis and response to treatment, producing clinically meaningful outcomes.
Inhaled corticosteroids: managing side effectsSubscription
Inhaled corticosteroids are commonly prescribed but need careful management to minimise the risk of side effects.
Our concerns with Relvar ElliptaSubscription
We would like to alert pharmacists to the potential for inadvertent dosing errors that may occur when patients are prescribed the new Relvar Ellipta (fluticasone furoate/vilanterol) inhaler for asthma or chronic obstructive pulmonary disease. Pharmacists should be alert to the fact that the licensed strengths of Relvar Ellipta (92µg/22µg and 184µg/22µg) are equivalent to medium to high doses of fluticasone propionate (500µg and 1,000µg, respectively). There is no low-dose inhaled corti
Primum non nocereSubscription